A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
← catalyst calendarNCT07029737 · readout in 499 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Apices Soluciones S.L..
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
55estimated
Sites
22
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-09-05 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-06-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mantle-cell Lymphoma
Interventions
- Drug: Acalabrutinib + R-CHOP standard of care — also filed as Induction Phase
- Drug: Acalabrutinib combination with Rituximab — also filed as Maintenance Phase
- Drug: Acalabrutinib monotherapy — also filed as Maintenance Phase
Primary outcome
what the primary-completion date above is the date OFBest Overall Response Rate (ORR)
measured From acalabrutinib start to approximately 1 year thereafter
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed